Haisma, Prof. Hidde
Hidde J. Haisma (1957) is professor of Pharmaceutic Gene Modulation at the Pharmacy department of the Faculty of Science and Engineering. He studied medical biology at Utrecht University and has worked in the US (including at Harvard Medical School) and at VU University Amsterdam. In 2000 he was appointed Professor of Pharmaceutic Gene Modulation at the University of Groningen.
Haisma conducts research into the development of drugs that can influence human genes in order to cure diseases. Haisma is editor of a number of journals in the field of gene therapy and has written over 100 publications and various patent applications in his field of study. Haisma is a board member of the Nederlandse Vereniging voor Gen- en Celtherapie (Dutch Society for Gene and Cell Therapy) and of the European Society of Gene and Cell Therapy. He is also a member of the Gene Doping Expert Group of the World Anti-Doping Agency (WADA). October 2016 he received a 100,000 US dollar grant from the WADA for his research project that will focus on the development of a gene doping detection assay based on next generation sequencing.
Video
- Haisma in NPO's Sportlab Sedoc on sport and genes (Dutch tv)
- Golden genes (Dutch tv, Labyrint)
- Haisma in TV programme Zembla: The Doping Theatre
Previously in the news
- Suspicious genes, fast legs
- Research grant from the World Anti-Doping Agency for professor Hidde Haisma
- Controleurs kunnen gendoping detecteren bij Winterspelen [Inspectors will be able to detect gene doping at Winter Games - in Dutch, source: de Volkskrant; infographic by Izaak Besuijen]
- Gene doping? No way back (in Dutch)
- With your genes? Try swimming (article in NRC on selection of sporters)
2021
Diaz
Arguello, O. A., & Haisma, H. J. (2021).
Apoptosis-Inducing TNF Superfamily Ligands for Cancer
Therapy. Cancers, 13(7),
[1543]. https://doi.org/10.3390/cancers13071543
2020
Liu,
B., Diaz Arguello, O. A., Chen, D., Chen,
S., Saber, A., & Haisma, H. J. (2020).
CRISPR-mediated ablation of overexpressed EGFR in combination
with sunitinib significantly suppresses renal cell carcinoma
proliferation. PLoS ONE,
15(5), [0232985]. https://doi.org/10.1371/journal.pone.0232985
van
den Boom, N. A. C., Winters, M., Haisma, H. J., &
Moen, M. H. (2020). Efficacy of Stem Cell Therapy for Tendon
Disorders: A Systematic Review. Orthopaedic
journal of sports medicine, 8(4). https://doi.org/10.1177/2325967120915857
Liu,
B., Chen, D., Chen, S., Saber, A.,
& Haisma, H. (2020). Transcriptional activation of
cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung
cancer. Biochemical Pharmacology,
178, [114095]. https://doi.org/10.1016/j.bcp.2020.114095
2019
Saber,
A., Liu, B., Ebrahimi, P., & Haisma, H. J. (2020).
CRISPR/Cas9 for overcoming drug resistance in solid
tumors. Daru : journal of Faculty of Pharmacy,
Tehran University of Medical Sciences, 28(1),
295-304. https://doi.org/10.1007/s40199-019-00240-z
Liu,
B., Chen, S., Chen, D., Cao,
F., Zwinderman, M., Kiemel, D., Aïssi, M.,
Dekker, F. J., Haisma, H. J., & La Rose, A.
(2020). Inhibition of histone deacetylase 1 (HDAC1) and HDAC2
enhances CRISPR/Cas9 genome editing. Nucleic Acids
Research, 48(2), 517-532. https://doi.org/10.1093/nar/gkz1136
de
Boer, E. N., van der Wouden, P. E., Johansson,
L. F., van Diemen, C. C., & Haisma,
H. J. (2019). A next-generation sequencing method for
gene doping detection that distinguishes low levels of plasmid DNA
against a background of genomic DNA. Gene
Therapy, 26(7-8), 338-346. https://doi.org/10.1038/s41434-019-0091-6
Liu,
B., Saber, A., & Haisma, H. J. (2019).
CRISPR/Cas9: A powerful tool for identification of new
targets for cancer treatment. Drug Discovery
Today, 24(4), 955-970. https://doi.org/10.1016/j.drudis.2019.02.011
Liu,
B., Song, S., Setroikromo, R.,
Chen, S., Hu, W., Chen, D., van der Wekken, A.
J., Melgert, B. N., Timens,
W., van den Berg, A., Saber, A., &
Haisma, H. J. (2019). CX Chemokine Receptor 7
Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer
upon Loss of Epidermal Growth Factor Receptor.
Cancers, 11(4), [455]. https://doi.org/10.3390/cancers11040455
Zhang,
B., Liu, B., Chen, D., Setroikromo, R.,
Haisma, H. J., & Quax, W. J. (2019).
Histone Deacetylase Inhibitors Sensitize TRAIL-Induced
Apoptosis in Colon Cancer Cells.
Cancers, 11(5), [645]. https://doi.org/10.3390/cancers11050645
2017
Bosch,
van den, T., Leus, N. G. J., Wapenaar, H., Boichenko, A.,
Hermans, J., Bischoff, R., Haisma, H.
J., & Dekker, F. J. (2017). A
6-alkylsalicylate histone acetyltransferase inhibitor inhibits
histone acetylation and pro-inflammatory gene expression in murine
precision-cut lung slices. Pulmonary Pharmacology
& Therapeutics, 44, 88-95. https://doi.org/10.1016/j.pupt.2017.03.006
Leus,
N. G. J., van den Bosch, T., van der Wouden, P. E.,
Krist, K., Ourailidou, M. E., Eleftheriadis, N., Kistemaker, L. E.
M., Bos, S., Gjaltema, R. A. F., Mekonnen, S.
A., Bischoff, R., Gosens, R.,
Haisma, H. J., & Dekker, F. J. (2017).
HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7
macrophages and reduces cigarette smoke-induced airway inflammation
in mice. Scientific Reports,
7, [45047]. https://doi.org/10.1038/srep45047
Pas,
H. I. M. F. L., Moen, M. H., Haisma, H. J., &
Winters, M. (2017). No evidence for the use of stem cell
therapy for tendon disorders: a systematic review.
British Journal of Sports Medicine,
51(13), 996-1004. https://doi.org/10.1136/bjsports-2016-096794
Pas,
H. I. M. F. L., Winters, M., Haisma, H. J., Koenis, M.
J. J., Tol, J. L., & Moen, M. H. (2017). Stem cell
injections in knee osteoarthritis: a systematic review.
British Journal of Sports Medicine,
51(15), 1125-1133. https://doi.org/10.1136/bjsports-2016-096793
Wapenaar,
H., van den Bosch, T., Leus, N. G. J., van der Wouden, P.
E., Eleftheriadis, N., Hermans, J., Hailu, G.
S., Rotili, D., Mai, A., Domling, A., Bischoff,
R., Haisma, H. J., & Dekker, F.
J. (2017). The relevance of K-i calculation for
bi-substrate enzymes illustrated by kinetic evaluation of a novel
lysine (K) acetyltransferase 8 inhibitor. European
Journal of Medicinal Chemistry, 136, 480-486.
https://doi.org/10.1016/j.ejmech.2017.05.015
2016
Arabpour,
M., Cool, R., Faber, K. N., Quax,
W. J., & Haisma, H. J. (2017).
Receptor-specific TRAIL as a means to achieve targeted
elimination of activated hepatic stellate cells.
Journal of Drug Targeting, 25(4),
360-369. https://doi.org/10.1080/1061186X.2016.1262867
Haisma,
H., & Schalekamp, T. (2016). Apothekersopleidingen
klaar voor de toekomst: Domeinspecifiek referentiekader en Raamplan
Farmacie geven onderwijs richting. Pharmaceutisch
Weekblad, 151(24), 18-19. http://www.pw.nl/achtergrond/2016/apothekersopleidingen-klaar-voor-de-toekomst
Haisma,
H., & Schalekamp, T. (2016, May 10).
Domeinspecifiek referentiekader & Raam plan Farmacie
2016. https://www.knmp.nl/downloads/domeinspecifiek-referentiekader-en-raamplan-farmacie-2016.pdf/view
Leus,
N. G. J., van der Wouden, P. E., van den Bosch, T.,
Hooghiemstra, W. T. R., Ourailidou, M. E., Kistemaker, L. E.
M., Bischoff, R., Gosens, R.,
Haisma, H. J., & Dekker, F. J. (2016).
HDAC 3-selective inhibitor RGFP966 demonstrates
anti-inflammatory properties in RAW 264.7 macrophages and mouse
precision-cut lung slices by attenuating NF-κB p65
transcriptional activity. Biochemical
Pharmacology, 58-74. https://doi.org/10.1016/j.bcp.2016.03.010
Haisma,
H. (2016). Nederlands farmaceutisch onderwijs
wereldwijd voorop. Pharmaceutisch
Weekblad, 151(50), 21.
van
den Bosch, T., Boichenko, A., Leus, N. G. J., Ourailidou, M. E.,
Wapenaar, H., Rotili, D., Mai, A., Imhof, A., Bischoff,
R., Haisma, H. J., & Dekker, F.
J. (2016). The histone acetyltransferase p300
inhibitor C646 reduces pro-inflammatory gene expression and
inhibits histone deacetylases. Biochemical
Pharmacology, 102, 130-140. https://doi.org/10.1016/j.bcp.2015.12.010
2014
Haisma,
H. (2014). Assessment of preclinical gene therapy
studies worldwide. (3 ed.) COGEM.
Haisma,
H. (2014). Sport: vliegensvlugge genen. In
Genen en Gezondheid (Vol. Cahier 1). Stichting
Biowetenschappen en Maatschappij.
Arabpour,
M., Poelstra, K., Helfrich, W.,
Bremer, E., & Haisma, H. J. (2014).
Targeted elimination of activated hepatic stellate cells by
an anti-epidermal growth factor-receptor single chain fragment
variable antibody-tumor necrosis factor-related apoptosis-inducing
ligand (scFv425-sTRAIL). Journal of gene
medicine, 16(9-10), 281-290. https://doi.org/10.1002/jgm.2776
Arabpour,
M., Poelstra, K., Helfrich, W.,
Bremer, E., & Haisma, H. J. (2014).
Targeted Elimination of Activated Hepatic Stellate Cells by
Anti-EGF-Receptor scFv-sTRAIL Fusion Protein.
Molecular Therapy, 22(suppl. 1),
S121-S121.
2013
Wisastra,
R., Kok, P. A. M., Eleftheriadis, N., Baumgartner, M. P., Camacho,
C. J., Haisma, H. J., & Dekker, F. J.
(2013). Discovery of a novel activator of 5-lipoxygenase from
an anacardic acid derived compound collection.
Bioorganic & Medicinal Chemistry,
21(24), 7763-7778. https://doi.org/10.1016/j.bmc.2013.10.015
van
der Gronde, T., de Hon, O., Haisma, H. J., &
Pieters, T. (2013). Gene doping: An overview and current
implications for athletes. British Journal of
Sports Medicine, 47(11), 670-678. https://doi.org/10.1136/bjsports-2012-091288
van
Dijk, R., Miranda, P. S. M., Riviere, C., ten Bloemendaal, L., van
Gorp, J., Duijst, S., de Waart, D. R., Beuers, U., Haisma, H.
J., & Bosma, P. J. (2013). Polyinosinic acid
blocks adeno-associated virus macrophage endocytosis in vitro and
enhances adeno-associated virus liver directed gene therapy in
vivo. Human Gene Therapy,
24(12), A135.
van
Dijk, R., Montenegro-Miranda, P. S., Riviere, C., Schilderink, R.,
ten Bloemendaal, L., van Gorp, J., Duijst, S., de Waart, D. R.,
Beuers, U., Haisma, H. J., & Bosma, P. J. (2013).
Polyinosinic Acid Blocks Adeno-Associated Virus Macrophage
Endocytosis In Vitro and Enhances Adeno-Associated Virus
Liver-Directed Gene Therapy In Vivo. Human Gene
Therapy, 24(9), 807-813. https://doi.org/10.1089/hum.2013.086
Kuldo,
J. M., Asgeirsdottir, S. A., Zwiers, P. J., Bellu, A.
R., Rots, M. G., Schalk, J. A. C., Ogawara, K. I.,
Trautwein, C., Banas, B., Haisma, H. J., Molema,
G., & Kamps, J. A. A. M. (2013).
Targeted adenovirus mediated inhibition of NF-kappa
B-dependent inflammatory gene expression in endothelial cells in
vitro and in vivo. Journal of Controlled
Release, 166(1), 57-65. https://doi.org/10.1016/j.jconrel.2012.12.016
2012
Wisastra,
R., Ghizzoni, M., Boltjes, A., Haisma, H.
J., & Dekker, F. J. (2012). Anacardic
acid derived salicylates are inhibitors or activators of
lipoxygenases. Bioorganic & Medicinal
Chemistry, 20(16), 5027-5032. https://doi.org/10.1016/j.bmc.2012.06.019
Farinha
Antunes, I., Doorduin, J., Haisma, H.
J., Elsinga, P. H., van Waarde,
A., Willemsen, A. T. M., Dierckx, R.
A., & de Vries, E. F. J. (2012).
F-18-FEAnGA for PET of beta-Glucuronidase Activity in
Neuroinflammation. Journal of Nuclear
Medicine, 53(3), 451-458. https://doi.org/10.2967/jnumed.111.096388
Antunes,
I. F., Haisma, H. J., Elsinga, P.
H., Sijbesma, J. W. A., van Waarde, A.,
Willemsen, A. T. M., Dierckx, R. A.,
& de Vries, E. F. J. (2012). In vivo evaluation of
[F-18]FEAnGA-Me: a PET tracer for imaging beta-glucuronidase
(beta-GUS) activity in a tumor/inflammation rodent model.
Nuclear Medicine and Biology, 39(6),
854-863. https://doi.org/10.1016/j.nucmedbio.2012.02.002
Farinha
Antunes, I., Haisma, H. J., Elsinga, P.
H., van Waarde, A., Willemsen, A. T.
M., Dierckx, R. A., & de Vries, E. F.
J. (2012). In Vivo Evaluation of
1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O-beta-D-Glucopyronuronate:
A Positron Emission Tomographic Tracer for Imaging
beta-Glucuronidase Activity in a Tumor/Inflammation Rodent
Model. Molecular imaging,
11(1), 77-87. https://doi.org/10.2310/7290.2011.00029
Farinha
Antunes, I., Haisma, H. J., Elsinga, P.
H., Di Gialleonardo, V., van Waarde, A.,
Willemsen, A. T. M., Dierckx, R. A.,
& de Vries, E. F. J. (2012). Induction of
beta-Glucuronidase Release by Cytostatic Agents in Small
Tumors. Molecular pharmaceutics,
9(11), 3277-3285. https://doi.org/10.1021/mp300327w
Haisma,
H. J. (2012). Physical Enhancement. In J.
Savulescu, R. ter Meulen, & G. Kahane (Eds.), Enhancing
human capacities (pp. 257-265). Wiley-Blackwell.
Ghizzoni,
M., Wu, J., Gao, T., Haisma, H. J., Dekker, F.
J., & Zheng, Y. G. (2012). 6-alkylsalicylates are
selective Tip60 inhibitors and target the acetyl-CoA binding
site. European Journal of Medicinal
Chemistry, 47(1), 337-344. https://doi.org/10.1016/j.ejmech.2011.11.001
2011
Wisastra,
R., Poelstra, K., Bischoff, R.,
Maarsingh, H., Haisma, H. J., & Dekker, F.
J. (2011). Antibody-Free Detection of Protein Tyrosine
Nitration in Tissue Sections.
ChemBioChem, 12(13), 2016-2020. https://doi.org/10.1002/cbic.201100148
Varkouhi,
A. K., Scholte, M., Storm, G., & Haisma, H. J.
(2011). Endosomal escape pathways for delivery of
biologicals. Journal of Controlled
Release, 151(3), 220-228. https://doi.org/10.1016/j.jconrel.2010.11.004
Ghizzoni,
M., Haisma, H. J., Maarsingh, H., & Dekker,
F. J. (2011). Histone acetyltransferases are crucial
regulators in NF-kappa B mediated inflammation.
Drug Discovery Today, 16(11-12),
504-511. https://doi.org/10.1016/j.drudis.2011.03.009
Wisastra,
R., Ghizzoni, M., Maarsingh, H., Minnaard, A.
J., Haisma, H. J., & Dekker, F.
J. (2011). Isothiazolones; thiol-reactive inhibitors
of cysteine protease cathepsin B and histone acetyltransferase
PCAF. Organic and Biomolecular
Chemistry, 9(6), 1817-1822. https://doi.org/10.1039/c0ob00464b
Haisma,
H. J., & Bellu, A. R. (2011). Pharmacological
Interventions for Improving Adenovirus Usage in Gene
Therapy. Molecular pharmaceutics,
8(1), 50-55. https://doi.org/10.1021/mp100310h
2010
van
Zeeburg, H. J. T., van Beusechem, V. W., Huizenga, A.,
Haisma, H. J., Korokhov, N., Gibbs, S., Leemans, C. R.,
& Brakenhoff, R. H. (2010). Adenovirus retargeting to
surface expressed antigens on oral mucosa. Journal
of gene medicine, 12(4), 365-376. https://doi.org/10.1002/jgm.1447
Ghizzoni,
M., Boltjes, A., de Graaf, C.,
Haisma, H. J., & Dekker, F. J. (2010).
Improved inhibition of the histone acetyltransferase PCAF by
an anacardic acid derivative. Bioorganic &
Medicinal Chemistry, 18(16), 5826-5834. https://doi.org/10.1016/j.bmc.2010.06.089
Haisma,
H. J., Kamps, G. K., Bouma, A., Geel, T. M., Rots, M.
G., Kariath, A., & Bellu, A. R. (2010). Selective
targeting of adenovirus to alpha(v)beta(3) integrins, VEGFR2 and
Tie2 endothelial receptors by angio-adenobodies.
International Journal of Pharmaceutics,
391(1-2), 155-161. https://doi.org/10.1016/j.ijpharm.2010.02.032
Farinha
Antunes, I., Haisma, H. J., Elsinga, P.
H., Dierckx, R. A., & de Vries, E. F.
J. (2010). Synthesis and Evaluation of [F-18]-FEAnGA
as a PET Tracer for beta-Glucuronidase Activity.
BIOCONJUGATE CHEMISTRY, 21(5),
911-920. https://doi.org/10.1021/bc9004602
2009
ABEN
RENE WILHELMUS, MARIE., SCHEEREN JOHAN, WILHELM., CORNELISSEN
JEROEN JOHANNES LAMBERTUS, MARIA., DE VOS, DICK., &
Haisma, H. (2009). ESTER OF GLUCURONIDE
PRODRUG OF ANTHRACYCLINE AND METHOD OF PREPARATION AND USE IN
TUMOR-SELECTIVE CHEMOTHERAPY. (Patent No.
JP2009215295).
Aben,
R. W. M., de Vos, D., Haisma, H. J., Cornelissen, J.
J. L. M., & Scheeren, J. W. (2009, Mar 1). Esters of
glucuronide prodrugs of anthracyclines and method of preparation
and use in tumor-selective chemotherapy. Google
Patents.
Dekker,
F. J., & Haisma, H. J. (2009).
Histone acetyl transferases as emerging drug targets.
Drug Discovery Today, 14(19-20),
942-948. https://doi.org/10.1016/j.drudis.2009.06.008
Dekker,
F. J., Ghizzoni, M., van der Meer, N., Wisastra, R.,
& Haisma, H. J. (2009). Inhibition of the PCAF
histone acetyl transferase and cell proliferation by
isothiazolones. Bioorganic & Medicinal
Chemistry, 17(2), 460-466. https://doi.org/10.1016/j.bmc.2008.12.008
Ghizzoni,
M., Haisma, H. J., & Dekker, F. J.
(2009). Reactivity of isothiazolones and
isothiazolone-1-oxides in the inhibition of the PCAF histone
acetyltransferase. European Journal of Medicinal
Chemistry, 44(12), 4855-4861. https://doi.org/10.1016/j.ejmech.2009.07.025
Haisma,
H. J., Boesjes, M., Beerens, A. M., van der Strate, B.
W. A., Curiel, D. T., Plueddemann, A., Gordon, S., &
Bellu, A. R. (2009). Scavenger Receptor A: A New Route for
Adenovirus 5. Molecular pharmaceutics,
6(2), 366-374. https://doi.org/10.1021/mp8000974
2008
Riezebos-Brilman,
A., Walczak, M., Regts, J., Rots, M. G., Kamps, G.,
Dontje, B., Haisma, H. Y., Wilschut,
J., & Daemen, T. (2008). A
comparative study on the immunotherapeutic efficacy of recombinant
Semliki Forest virus and adenovirus vector systems in a murine
model for cervical cancer (vol 14, pg 1695, 2007).
Gene Therapy, 15(1), 66. https://doi.org/10.1038/sj.gt.3303084
Johnson,
T. S., Mahnke, K., Storn, V., Schoenfeld, K., Ring, S., Nettelbeck,
D. M., Haisma, H. J., Le Gall, F., Kontermann, R. E.,
& Enk, A. H. (2008). Inhibition of Melanoma Growth by
Targeting of Antigen to Dendritic Cells via an Anti-DEC-205
Single-Chain Fragment Variable Molecule. Clinical
Cancer Research, 14(24), 8169-8177. https://doi.org/10.1158/1078-0432.CCR-08-1474
Schoemaker,
M. H., Rots, M. G., Beljaars, L., Ypma,
A. Y., Jansen, P. L. M., Poelstra, K., Moshage,
A., & Haisma, H. J. (2008).
PDGF-receptor beta-targeted adenovirus redirects gene
transfer from hepatocytes to activated stellate cells.
Molecular pharmaceutics, 5(3),
399-406. https://doi.org/10.1021/mp700118p
Haisma,
H. J., Kamps, J. A. A. M., Plantinga, J.
A., Rots, M. G., Bellu, A. R., & Kamps, G.
(2008). Polyinosinic acid enhances delivery of adenovirus
vectors in vivo by preventing sequestration in liver
macrophages. Journal of general
virology, 89, 1097-1105. https://doi.org/10.1099/vir.0.83495-0
Bremer,
E., van Dam, G. M., de Bruyn, M.,
van Riezen, M., Dijkstra, M., Kamps, G., Helfrich,
W., & Haisma, H. (2008). Potent
Systemic Anticancer Activity of Adenovirally Expressed
EGFR-Selective TRAIL Fusion Protein. Molecular
Therapy, 16(12), 1919-1926. https://doi.org/10.1038/mt.2008.203
Beerens,
A. M. J., Rots, M. G., Bermudez, B., De Vries,
E. F. J., & Haisma, H. J. (2008).
Secretion of thymidine kinase to increase the effectivity of
suicide gene therapy results in the loss of enzymatic
activity. Journal of Drug Targeting,
16(1), 26-35.
Farinha
Antunes, I., Haisma, H. J., & de
Vries, E. F. J. (2008). Tumor-specific activation of
prodrugs: Is there a role for nuclear medicine?
Nuclear Medicine Communications,
29(10), 845-846. https://doi.org/10.1097/MNM.0b013e3283094efc
2007
Riezebos-Brilman,
A., Walczak, M., Regts, J., Rots, M., Kamps, G.,
Dontje, B., Haisma, H., Wilschut,
J., & Daemen, T. (2007). A
comparative study on the immunotherapeutic efficacy of recombinant
Semliki Forest virus and adenovirus vector systems in a murine
model for cervical cancer. Gene
Therapy, 14(24), 1695-1704. https://doi.org/10.1038/sj.gt.3303036
Carette,
J. E., Graat, H. C. A., Schagen, F. H. E., Mastenbroek, D. C.
J., Rots, M. G., Haisma, H. J.,
Groothuis, G. M. M., Schaap, G. R., Bras, J., Kaspers, G. J.
L., Wuisman, P. I. J. M., Gerritsen, W. R., & van Beusechem, V.
W. (2007). A conditionally replicating adenovirus with strict
selectivity in killing cells expressing epidermal growth factor
receptor. Virology, 361(1),
56-67. https://doi.org/10.1016/j.virol.2006.11.011
Gommans,
W. M., McLaughlin, P. M. J., Lindhout, B. I., Segal, D. J.,
Wiegman, D. J., Haisma, H. J., van der Zaal, B.
J., & Rots, M. G. (2007). Engineering zinc
finger protein transcription factors to downregulate the epithelial
glycoprotein-2 promoter as a novel anti-cancer treatment.
Molecular carcinogenesis, 46(5),
391-401. https://doi.org/10.1002/mc.20289
Beerens,
A. M. J., Rots, M. G., de Vries, E. F.
J., & Haisma, H. J. (2007). Fusion of
herpes simplex virus thymidine kinase to VP22 does not result in
intercellular trafficking of the protein.
International journal of molecular medicine,
19(5), 841-849.
Gommans,
W. M., McLaughlin, P. M. J., Schalk, J. A. C., Groothuis, G.
M. M., Haisma, H. J., & Rots, M.
G. (2007). Highly efficient and carcinoma-specific
adenoviral replication restricted by the EGP-2 promoter.
Journal of Controlled Release,
117(1), 1-10. https://doi.org/10.1016/j.jconrel.2006.10.006
2006
Rots,
MG., Elferink, MGL., Gommans, WM., Oosterhuis,
D., Schalk, JAC., Curiel, DT., Olinga,
P., Haisma, HJ., & Groothuis,
GMM. (2006). An ex vivo human model system to evaluate
specificity of replicating and non-replicating gene therapy
agents. Journal of gene medicine,
8(1), 35-41. https://doi.org/10.1002/jgm.815
Stoff-Khalili,
M. A., Rivera, A. A., Le, L. P., Stoff, A., Everts, M., Contreras,
J. L., Chen, D., Teng, L., Rots, M. G., Haisma,
H. J., Rocconi, R. P., Bauerschmitz, G. J., Rein, D. T.,
Yamamoto, M., Siegal, G. P., Dall, P., Michael Mathis, J., &
Curiel, D. T. (2006). Employment of liver tissue slice
analysis to assay hepatotoxicity linked to replicative and
nonreplicative adenoviral agents. Cancer Gene
Therapy, 13(6), 606-618. https://doi.org/10.1038/sj.cgt.7700934
Ogawara,
K., Kuldo, JM., Oosterhuis, K., Kroesen, BJ.,
Rots, MG., Trautwein, C., Kimura, T., Haisma,
HJ., & Molema, G. (2006). Functional
inhibition of NF-kappa B signal transduction in alpha v alpha beta
3 integrin expressing endothelial cells by using RGD-PEG-modified
adenovirus with a mutant I kappa B gene. Arthritis
Research and Therapy, 8(1), [32]. https://doi.org/10.1186/ar1885
Haisma,
HJ., & de Hon, O. (2006). Gene doping.
International Journal of Sports Medicine,
27(4), 257-266. https://doi.org/10.1055/s-2006-923986
Haisma,
HJ., De Hon, O., Sollie, P., & Vorstenbosch, J. (2006).
Genetische doping. Nederlands Tijdschrift
voor Klinische Chemie en Laboratoriumgeneeskunde,
31(1), 19.
Karpanen,
T., Wirzenius, M., Mäkinen, T., Veikkola, T., Haisma, H.
J., Achen, M. G., Stacker, S. A., Pytowski, B.,
Ylä-Herttuala, S., & Alitalo, K. (2006).
Lymphangiogenic growth factor responsiveness is modulated by
postnatal lymphatic vessel maturation. American
Journal of Pathology, 169(2), 708-718. https://doi.org/10.2353/ajpath.2006.051200
Mahasreshti,
PJ., Kataram, M., Wu, HJ., Yalavarthy, LP., Carey, D., Dent, P.,
Chada, S., Alvarez, RD., Haisma, HJ., Fisher, PB.,
& Curiel, DT. (2006). Ovarian cancer targeted
adenoviral-mediated mda-7/IL-24 gene therapy.
Gynecologic Oncology, 100(3),
521-532. https://doi.org/10.1016/j.ygyno.2005.08.042
Visser,
A. E., Verschure, P. J., Gommans, W. M., Haisma, H.
J., & Rots, M. G. (2006). Step into
the Groove: Engineered Transcription Factors as Modulators of Gene
Expression. In JC. Hall, JC. Dunlap, T. Friedmann, &
VanHeyningen (Eds.), ADVANCES IN GENETICS (pp. 131-+).
(Advances in Genetics; Vol. 56). Academic Press. https://doi.org/10.1016/S0065-2660(06)56004-3
Gommans,
WM., van Eert, SJ., McLaughlin, PMJ., Harmsen, MC.,
Yamamoto, M., Curiel, DT., Haisma, HJ., &
Rots, MG. (2006). The carcinoma-specific epithelial
glycoprotein-2 promoter controls efficient and selective gene
expression in an adenoviral context. Cancer Gene
Therapy, 13(2), 150-158. https://doi.org/10.1038/sj.cgt.7700882
Gommans,
W. M., Oosterhuis, D., Dmitriev, I., Schaack, J.,
Curiel, D. T., Haisma, H. J., & Rots, M.
G. (2006). Towards a double controlled conditionally
replicative adenovirus for potent and specific melanoma cell
kill. Journal of Controlled Release,
116(2), E64-E66. https://doi.org/10.1016/j.jconrel.2006.09.052
2005
Oosterhoff,
D., Overmeer, RM., de Graaf, M., van der Meulen, IH., Giaccone, G.,
van Beusechem, VW., Haisma, HJ., Pinedo, HM., &
Gerritsen, WR. (2005). Adenoviral vector-mediated expression
of a gene encoding secreted, EpCAM-targeted carboxylesterase-2
sensitises colon cancer spheroids to CPT-11.
British Jounal of Cancer, 92(5),
882-887. https://doi.org/10.1038/sj.bjc.6602362
Roy,
H., Bhardwaj, S., Babu, M., Jauhiainen, S., Herzig, KH., Bellu,
AR., Haisma, HJ., Carmeliet, P., Alitalo, K., &
Yla-Herttuala, S. (2005). Adenovirus-mediated gene transfer
of placental growth factor to perivascular tissue induces
angiogenesis via upregulation of the expression of endogenous
vascular endothelial growth factor-A. Human Gene
Therapy, 16(12), 1422-1428.
Gommans,
WM., Haisma, HJ., & Rots, MG. (2005).
Engineering zinc finger protein transcription factors: The
therapeutic relevance of switching endogenous gene expression on or
off at command. Journal of Molecular
Biology, 354(3), 507-519. https://doi.org/10.1016/j.jmb.2005.06.082
Lu,
B., Makhija, SK., Nettelbeck, DM., Rivera, AA., Komarova, S., Zhou,
F., Yamamoto, M., Haisma, HJ., Alvarez, RD., Curiel,
DT., & Zhu, ZB. (2005). Evaluation of tumor-specific
promoter activities in melanoma. Gene
Therapy, 12(4), 330-338. https://doi.org/10.1038/sj.gt.3302385
Kraaij,
R., van Rijswijk, ALCT., Haisma, HJ., & Bangma,
CH. (2005). Prostate specific membrane antigen (PSMA) is a
tissue-specific target for adenoviral transduction of prostate
cancer in vitro. Prostate,
62(3), 253-259. https://doi.org/10.1002/pros.20150
Buursma,
A. R., Beerens, A., de Vries, E. F. J., van
Waarde, A., Rots, M., Hospers, G. A.
P., Vaalburg, W., & Haisma, H. J. (2005).
The human norepinephrine transporter in combination with
C-11-m-hydroxyephedrine as a reporter gene/reporter probe for PET
of gene therapy. Journal of Nuclear
Medicine, 46(12), 2068-2075.
Haisma,
H. J., & de Hon, O. (2005). Ziek, beter, best: van
gentherapie tot genetische doping. In Beter dan Goed,
over Genetica en de toekomst van Topsport (pp. 120 - 137).
Veen Magazines B.V..
2004
Nevalainen,
T. J., Scheeren, H. W., Pinedo, H. M., Haisma, H. J.,
& Boven, E. (2004). A methylester of the glucuronide
prodrug DOX-GA3 for improvement of tumor-selective
chemotherapy. Biochemical
Pharmacology, 68(11), 2273-2281. https://doi.org/10.1016/j.bcp.2004.08.004
Kirby,
TO., Rivera, A., Rein, D., Ulasov, N. V., Breidenbach, M., Kataram,
M., Contreras, JL., Krumdieck, C., Yamamoto, M., Rots,
MG., Haisma, HJ., Alvarez, RD., Mahasreshti,
PJ., & Curiel, DT. (2004). A novel ex vivo model system
for evaluation of conditionally replicative adenoviruses
therapeutic efficacy and toxicity. Clin.Cancer
Res., 10(24), 8697 - 8703.
Ogawara,
K., Rots, M., Kok, R. J., Moorlag, H. E.,
van Loenen - Weemaes, A., Meijer, D. K. F., Haisma, H.
J., & Molema, I. (2004). A novel
strategy to modify adenovirus tropism and enhance transgene
delivery to activated vascular endothelial cells in vitro and in
vivo. Human Gene Therapy,
15(5), 433 - 443. https://doi.org/10.1089/10430340460745766
Rots,
M., Gommans, W. M., Dmitriev, I., Oosterhuis,
D., Seki, T., Curiel, D. T., & Haisma, H.
J. (2004). A platform for constucting
infectivity-enhanced fiber-mosaic adenoviruses genetically modified
to express two fiber types. Gene Therapy and
Molecular Biology, 8, 1 - 8.
Leath,
CA., Kataram, M., Bhagavatula, P., Gopalkrishnan, RV., Dent, P.,
Fisher, PB., Pereboev, A., Carey, D., Lebedeva, N. V.,
Haisma, HJ., Alvarez, RD., Curiel, DT., & Mahasreshti,
PJ. (2004). Infectivity enhanced adenoviral-mediated
mda-7/IL-24 gene therapy for ovarian carcinoma.
Gynecologic Oncology, 94(2), 352 -
362. https://doi.org/10.1016/j.ygyno.2004.04.028
Pinedo,
H. M., Oosterhoff, D., Van der Meulen-Muileman, I. H., Gerritsen,
W. R., Haisma, H. J., & Boven, E. (2004).
Pronounced antitumor efficacy by extracellular activation of
a doxorubicin-glucuronide prodrug after adenoviral vector-mediated
expression of a human antibody-enzyme fusion protein.
Human Gene Therapy, 15(3), 229 -
238.
Schoemaker,
M., Conde de la Rosa, L., Buist-Homan, M., Vrenken, T.
E., Havinga, R., Poelstra, K.,
Haisma, H. J., Jansen, P. LM., & Moshage, A. J.
H. (2004). Tauroursodeoxycholic acid protects rat
hepatocytes from bile acid-induced apoptosis via activation of
survival pathways. Hepatology,
39(6), 1563 - 1573. https://doi.org/10.1002/hep.20246
2003
Brandao,
JG., Scheper, RJ., Lougheed, SM., Curiel, DT., Tillman, BW.,
Gerritsen, WR., van den Eertwegh, AJM., Pinedo, HM., Haisma,
HJ., & de Gruijl, TD. (2003). CD40-targeted
adenoviral gene transfer to dendritic cells through the use of a
novel bispecific single-chain Fv antibody enhances cytotoxic T cell
activation. Vaccine,
21(19-20), 2268-2272. https://doi.org/10.1016/S0264-410X(03)00050-1
van
Beusechem, V. W., Mastenbroek, D. C., Van den Doel, P. B., Lamfers,
M. L., Grill, J., Wurdinger, T., Haisma, H. J.,
Pinedo, H. M., & Gerritsen, W. R. (2003). Conditionally
replicative adenovirus expressing a targeting adapter molecule
exhibits enhanced oncolytic potency on CAR-deficient tumors.
Gene Therapy, 10(23), 1982-1991. https://doi.org/10.1038/sj.gt.3302103
Pinedo,
H. M., Quadir, R., Haisma, H. J., & Boven, E.
(2003). Cytosolic beta-glycosidases for activation of
glycoside prodrugs of daunorubicin.
Biochem.Pharmacol., 65(11),
1875-1881. https://doi.org/10.1016/S0006-2952(03)00183-7
Oosterhoff,
D., Witlox, M. A., van Beusechem, V. W., Haisma, H.
J., Schaap, G. R., Bras, J., Kruyt, W.,
Molenaar, B., Boven, E., Wuisman, P. I., Pinedo, H. M., &
Gerritsen, W. R. (2003). Gene-directed enzyme prodrug therapy
for osteosarcoma: Sensitization to CPT-11 in vitro and in vivo by
adenoviral delivery of a gene encoding secreted
carboxylesterase-2. Mol.Cancer Ther.,
2(8), 765-771.
Mahasreshti,
P. J., Kataram, M., Wang, M. H., Stockard, C. R., Grizzle, W. E.,
Carey, D., Siegal, G. P., Haisma, H. J., Alvarez, R.
D., & Curiel, D. T. (2003). Intravenous delivery of
adenovirus-mediated soluble FLT-1 results in liver toxicity.
Clin.Cancer Res., 9(7), 2701 -
2710.
Fonseca,
M. J., Jagtenberg, J. C., Haisma, H. J., & Storm,
G. (2003). Liposome-mediated targeting of enzymes to cancer
cells for site-specific activation of prodrugs: Comparison with the
corresponding antibody-enzyme conjugate.
Pharmaceutical Research, 20(3),
423-428.
Beerens,
A. M., Al Hadithy, A. F., Rots, M., &
Haisma, H. J. (2003). Protein transduction domains and
their utility in gene therapy. Curr.Gene
Ther., 3(5), 486 - 494.
Schoemaker,
M., Gommans, W. M., Conde de la Rosa, L., Buist-Homan,
M., Klok, P., Trautwein, C., van Goor,
H., Poelstra, K., Haisma, H. J.,
Jansen, P. LM., & Moshage, A. J. H. (2003).
Resistance of rat hepatocytes against bile acid-induced
apoptosis in cholestatic liver injury is due to nuclear
factor-kappa B activation. Journal of
Hepatology, 39(2), 153-161. https://doi.org/10.1016/S0168-8278(03)00214-9
Haisma,
HJ., & Rots, MG. (2003). State of the
art in gene therapy. In CTS. Sibinga, & LFM. DeLeij
(Eds.), CELLULAR ENGINEERING AND CELLULAR THERAPIES (pp.
171-187). (DEVELOPMENTS IN HEMATOLOGY AND IMMUNOLOGY; Vol. 38).
Springer.
Rots,
MG., Curiel, DT., Gerritsen, WR., & Haisma,
HJ. (2003). Targeted cancer gene therapy: the
flexibility of adenoviral gene therapy vectors.
J.Control Release, 87(1-3), 159-165.
https://doi.org/10.1016/S0168-3659(02)00360-7
Bruell,
D., Stocker, M., Huhn, M., Redding, N., Kupper, M., Schumacher, P.,
Paetz, A., Bruns, CJ., Haisma, HJ., Fischer, R.,
Finnern, R., & Barth, S. (2003). The recombinant anti-EGF
receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly
metastatic pancreatic carcinoma cell line.
Int.J.Oncol., 23(4),
1179-1186.
Uil,
T. G., Haisma, H. J., & Rots, M.
(2003). Therapeutic modulation of endogenous gene function by
agents with designed DNA-sequence specificities.
Nucleic Acids Res., 31(21),
6064-6078. https://doi.org/10.1093/nar/gkg815
| Last modified: | 21 December 2020 10.44 a.m. |